Table 3.
Crude- and multivariable-adjusted hazard ratios for cerebrovascular disease according to treatment modality in prostate cancer cohort
| Treatment group | N | Event | Person year | Incidence | H.R (95% Confidence interval) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Crude | Adjusted* | ||||||||
| IS | No medication | 1334 | 86 | 8185.07 | 10.51 | 1 | Ref. | Ref. | |
| GnRH agonists | 649 | 37 | 3200.95 | 11.56 | 1.156 | (0.785-1.702) | 0.978 | (0.655-1.460) | |
| Antiandrogen only | 153 | 6 | 609.68 | 9.84 | 1.001 | (0.437-2.292) | 0.822 | (0.354-1.910) | |
| CVD | No medication | 1316 | 107 | 8039.8 | 13.31 | 1 | Ref. | Ref. | |
| GnRH agonists | 639 | 44 | 3132.05 | 14.05 | 1.111 | (0.781-1.581) | 0.939 | (0.652-1.352) | |
| Antiandrogen only | 152 | 7 | 609.07 | 11.49 | 0.926 | (0.431-1.990) | 0.76 | (0.349-1.655) | |
* Adjusted for all covariated in Table 1